IFRS 2 Share-Based Payment: What Non-US Startups Actually Have to Expense

If your startup's financial statements are prepared under IFRS — or a local standard based on it, like Ind AS 102 in India, AASB 2 in Australia, or FRS 102 in the UK — every stock option, RSU, or phantom share you've granted has to be measured at fair value and expensed over its vesting period. This is IFRS 2, and it applies regardless of stage: a pre-revenue seed company owes it exactly as much as a company about to raise a Series B. Most founders outside the US only discover this when an auditor asks for it retroactively, which is also the most expensive way to find out.

The confusion is understandable. Almost everything written about equity compensation accounting assumes a Delaware C-corp under US GAAP, where the equivalent rule is called ASC 718. Founders in MENA, Africa, South Asia, and most of the rest of the world read that content, don't see their situation in it, and conclude the whole topic doesn't apply to them. It does — under a different name, with a different acronym, and usually with no one flagging it until the first audit.

What IFRS 2 actually requires

IFRS 2 covers any share-based payment transaction: stock options, RSUs, phantom shares settled in cash, and shares issued for goods or services from non-employees. For the equity grants most Seed-to-Series-B startups care about, the mechanics are consistent:

• Measure at grant date. The fair value of the option is fixed on the day it's granted, using an option-pricing model. It is not re-measured later because your share price went up, down, or your company got acquired. The grant-date number is the number.
• Spread it over the vesting period. If an option vests over four years, the expense is recognized over those four years, not as a lump sum on day one and not on exercise.
• It's non-cash, but it's still an expense. No cash leaves the company. The charge hits the income statement as a compensation cost, with the offsetting entry in equity. This is the detail founders most often miss: a non-cash expense is still an expense, and it still reduces reported profit.
• Re-estimate as you go. IFRS 2 requires you to estimate how many granted options will actually vest — accounting for expected forfeitures — and revise that estimate each reporting period as people leave or conditions change. This is a real divergence from US GAAP's ASC 718, where companies can elect to account for forfeitures as they happen instead of estimating upfront.

None of this is a formula you can approximate from a template. It's a recurring accounting exercise tied to every grant you issue, for as long as you're issuing grants under an IFRS-based framework.

Who this actually reaches

The trigger is your accounting framework, not your company's domicile or your employees' nationality — which is the opposite of how 409A works, and the source of most of the confusion. In practice:

• Most of MENA, Africa, and South Asia report under IFRS as issued by the IASB directly, with no local variant. A UAE, Saudi, Kenyan, Nigerian, or Pakistani startup preparing IFRS financial statements is squarely in scope the moment it grants its first option.
• India uses Ind AS 102, a near-identical local adoption of IFRS 2 under the Companies (Indian Accounting Standards) Rules.
• Australia and New Zealand use AASB 2 / NZ IFRS 2, again functionally the same standard under a local label.
• Singapore uses SB-FRS 102 for most companies, converging with IFRS 2 in substance.
• The UK gives private companies a choice: full IFRS, or FRS 102's own share-based payment section, which is simpler in places but built on the same grant-date fair-value logic.
• The US is the outlier here, not the default — ASC 718 governs instead, and it's the standard almost all equity-compensation content on the internet is actually written about, even when it doesn't say so.

If your company reports under any of the first five, "we don't do 409A valuations because we're not a Delaware company" is true and irrelevant — the accounting requirement you actually owe is IFRS 2, not its US cousin, and skipping it because you confirmed you don't need 409A is the exact trap 409A valuation outside the US is written to catch.

IFRS 2 vs ASC 718: why the confusion persists

These two standards answer the same question — what's the fair value of this option, and when do we expense it — on the same grant-date, fair-value-model foundation. Founders who've read US content assume "we did the Black-Scholes thing" covers them everywhere. Two differences matter in practice:

1. Forfeiture estimates. ASC 718 lets a US company elect to recognize forfeitures as they actually occur, which is simpler bookkeeping. IFRS 2 requires an upfront estimate of expected forfeitures, revised every period — more ongoing judgment, not a one-time calculation.
2. Nonemployee awards. IFRS 2 treats grants to non-employees (advisors, contractors) differently depending on whether they're for services similar to an employee's or for distinct goods and services, each measured differently. ASC 718's nonemployee treatment is more unified.

Neither difference changes the headline fact: if you're incorporated outside the US and reporting under IFRS or a local equivalent, ASC 718 content tells you the wrong mechanics for your own numbers, even though the underlying concept — expense it at grant-date fair value, over the vesting period — transfers directly.

Where the valuation actually comes from

IFRS 2 doesn't hand you a formula. It requires fair value, typically produced through an option-pricing model — Black-Scholes for straightforward options, a lattice or binomial model for anything with more complex vesting or performance conditions. The inputs that make this hard for a private company:

• Share price. Usually your last priced round, discounted for the difference between what investors paid for preferred shares and what a common option is actually worth.
• Expected volatility. A private company has no trading history, so volatility gets borrowed from a basket of comparable listed companies in the same sector and stage — a judgment call your accountant or a valuation specialist makes, not something a founder estimates from first principles.
• Expected life and risk-free rate. Standard inputs, usually drawn from government bond yields matching the option's expected term.

This is accountant-and-auditor territory, not a DIY spreadsheet exercise, and it's also not a one-time cost. Every tranche of options you grant gets its own grant-date valuation, because the share price and volatility inputs change as the company matures.

The expensive mistake: finding out at the Series A audit

The actual failure mode isn't getting the valuation wrong. It's not doing it at all until someone forces the question — usually the first statutory audit, or a Series A investor's due diligence team asking for audited financials. At that point, every option granted since incorporation needs a retrospective grant-date valuation, and the expense has to be reconstructed and restated across however many years of historical financials the audit covers. A company that's granted options quarterly for three years without ever running this calculation is looking at a multi-grant backlog, done all at once, under the time pressure of a live raise — instead of one grant at a time, as part of normal quarterly closes.

The second-order cost is diligence optics. An investor's counsel reading option grants with no corresponding expense history reads that as a company that hasn't done basic accounting hygiene — the same signal cap table cleanup before fundraising flags for messy ownership records, just on the P&L side instead of the ownership side.

What this means for how you track grants

The practical fix is boring and cheap compared to the retrospective version: capture the grant date, vesting schedule, instrument type, and valuation method at the moment each grant is approved, so your accountant has what they need every reporting period instead of reconstructing it later from board minutes and email threads. Govy tracks IFRS 2 (and 409A) compliance deadlines against every grant on its ledger, tied to the board resolution that approved it, so the record of when a valuation is due doesn't live in someone's calendar reminder that gets missed. Govy is not an IFRS 2 valuation provider — that calculation still comes from your accountant, auditor, or a specialist valuation firm. What it keeps is the paper trail those professionals need, attached permanently to the grant instead of scattered across a spreadsheet and a folder of PDFs. See how it works.

FAQ

Does my startup actually have to expense stock options under IFRS 2? If your financial statements are prepared under IFRS, or a local standard based on it — Ind AS 102 in India, AASB 2 in Australia, FRS 102 in the UK, SB-FRS 102 in Singapore — then yes, every option, RSU, or phantom share you've granted has to be measured at fair value and expensed over its vesting period. This applies whether you're pre-revenue or post-Series-B, and whether or not any cash changes hands. The requirement is triggered by your accounting framework, not your size or stage.

Is this the same as a 409A valuation? No. 409A is a US Internal Revenue Code provision that sets a defensible option strike price for US tax purposes, and it only reaches companies with US-taxpayer option holders. IFRS 2 is an accounting standard that values the same options for a completely different reason — booking the right expense on your income statement — and it applies based on which accounting framework governs your financial statements, not your option holders' tax residency. A Saudi or Kenyan company with zero US employees can owe an IFRS 2 valuation while owing nothing under 409A.

Does expensing stock options under IFRS 2 cost us cash? No. The fair value of the grant is recognized as a non-cash expense on the income statement, with the matching entry sitting in equity. Your bank balance doesn't move. What does move is your reported profit, which matters the moment an investor, auditor, or acquirer is reading your P&L and expects options to show up as a cost — not as a footnote.

Who actually calculates the IFRS 2 valuation for a private startup? Almost always your accountant or auditor, sometimes with a specialist valuation provider for the volatility and option-pricing inputs on a first-time or complex grant. The method is typically Black-Scholes or a lattice model, using expected volatility borrowed from comparable listed companies, since a private startup has no trading history of its own. It is not something a founder calculates alone in a spreadsheet, and it is not optional just because the company is pre-revenue.

What happens if we never bothered with this and now we're raising a Series A? Your auditor will ask for it retrospectively — every option grant since incorporation gets valued as of its original grant date, expensed over the vesting period that's already partly or fully elapsed, and restated into however many years of historical financials the audit covers. This is the single most common way IFRS 2 actually costs a founder real time and money: not the ongoing expense, but the multi-year catch-up calculation done under deal pressure instead of one grant at a time as you went.